Sökning: onr:"swepub:oai:DiVA.org:uu-437371" > Consensus on molecu...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05623naa a2200721 4500 | |
001 | oai:DiVA.org:uu-437371 | |
003 | SwePub | |
008 | 210309s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4373712 URI |
024 | 7 | a https://doi.org/10.1016/j.ejca.2021.01.0082 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Ambrosini, Valentina4 aut |
245 | 1 0 | a Consensus on molecular imaging and theranostics in neuroendocrine neoplasms |
264 | 1 | b Elsevier,c 2021 |
338 | a print2 rdacarrier | |
520 | a Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing 68gallium-labelled somatostatin analogue ([68Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing 18fluorine-fluoro-2-deoxyglucose ([18F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Consensus | |
653 | a Molecular imaging | |
653 | a Neuroendocrine neoplasms | |
653 | a PRRT | |
700 | 1 | a Kunikowska, Jolanta4 aut |
700 | 1 | a Baudin, Eric4 aut |
700 | 1 | a Bodei, Lisa4 aut |
700 | 1 | a Bouvier, Catherine4 aut |
700 | 1 | a Capdevila, Jaume4 aut |
700 | 1 | a Cremonesi, Marta4 aut |
700 | 1 | a de Herder, Wouter W4 aut |
700 | 1 | a Dromain, Clarisse4 aut |
700 | 1 | a Falconi, Massimo4 aut |
700 | 1 | a Fani, Melpomeni4 aut |
700 | 1 | a Fanti, Stefano4 aut |
700 | 1 | a Hicks, Rodney J4 aut |
700 | 1 | a Kabasakal, Levent4 aut |
700 | 1 | a Kaltsas, Gregory4 aut |
700 | 1 | a Lewington, Val4 aut |
700 | 1 | a Minozzi, Silvia4 aut |
700 | 1 | a Cinquini, Michela4 aut |
700 | 1 | a Öberg, Kjell,d 1946-u Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob |
700 | 1 | a Oyen, Wim J G4 aut |
700 | 1 | a O'Toole, Dermot4 aut |
700 | 1 | a Pavel, Marianne4 aut |
700 | 1 | a Ruszniewski, Philippe4 aut |
700 | 1 | a Scarpa, Aldo4 aut |
700 | 1 | a Strosberg, Jonathan4 aut |
700 | 1 | a Sundin, Anders,d 1954-u Uppsala universitet,Radiologi4 aut0 (Swepub:uu)anderssu |
700 | 1 | a Taïeb, David4 aut |
700 | 1 | a Virgolini, Irene4 aut |
700 | 1 | a Wild, Damian4 aut |
700 | 1 | a Herrmann, Ken4 aut |
700 | 1 | a Yao, James4 aut |
710 | 2 | a Uppsala universitetb Endokrin tumörbiologi4 org |
773 | 0 | t European Journal of Cancerd : Elsevierg 146, s. 56-73q 146<56-73x 0959-8049x 1879-0852 |
856 | 4 | u http://manuscript.elsevier.com/S0959804921000198/pdf/S0959804921000198.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-437371 |
856 | 4 8 | u https://doi.org/10.1016/j.ejca.2021.01.008 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy